Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation. Read why KRYS ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

With a strong foundation in CF therapies and an expanding pipeline in pain management and other areas, Vertex demonstrates solid financial health with a robust gross margin of 86.1% and revenue of ...

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed ...

Vertex’s pipeline is well-stocked, with four new drugs in Phase III-clinical trials (the final phase before regulatory approval) for type-1 diabetes, diabetic peripheral neuropathy, and two ...

While Vertex’s main focus is on the development and strengthening of its CF franchise, the company also has a rapidly advancing mid- to late-stage pipeline in other disease areas beyond CF ...

The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this. Whatever happens, though ...